Skip to main content

Table 1 Patients’ characteristics

From: Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer

Background

n (%)

Age

  < 70 years

275 (74)

  ≥ 70 years

99 (26)

Gender

 Male

322 (86)

 Female

52 (14)

ECOG performance status

 0

234 (63)

 1

121 (32)

 2

16 (4)

 3

3 (1)

Body mass index

  < 20

97 (26)

  ≥ 20

277 (74)

Primary site

 Larynx

57 (15)

 Nasopharynx

48 (13)

 Hypopharynx

132 (34)

 Nasal sinus

21 (6)

 Oropharynx

101 (27)

 Oral cavity

14 (4)

 Ear canal

1 (1)

T-classification

 1

32 (9)

 2

136 (36)

 3

86 (23)

 4a

92 (25)

 4b

28 (7)

N-classification

 0

76 (20)

 1

54 (15)

 2a

19 (5)

 2b

134 (36)

 2c

75 (20)

 3

16 (4)

Tumor histology

 SCC

347 (93)

 Others

27 (7)

Brinkman index

  < 500

131 (35)

  ≥ 500

243 (65)

Habitual alcoholic consumption

 Yes

221 (59)

 No

153 (41)

Use of ACEi or ARB

 Yes

69 (18)

 No

305 (82)

Use of PPI or H2 blocker

 Yes

198 (53)

 No

176 (47)

Oral hygiene before treatment

 Good

179 (48)

 Poor

183 (52)

Coexistence of other malignancies

 Yes

45 (12)

 No

329 (88)

Charlson comorbidity index

 0–1

293 (78)

  ≥ 2

81 (22)

Serum albumin before treatment

 Within normal limits

313 (84)

 Less than normal range

61 (16)

Hemoglobin before treatment

 Within normal limits

265 (71)

 Less than normal range

109 (29)

Use of sleeping pills before treatment?

 Yes

185 (49)

 No

189 (51)

Induction chemotherapy

 Yes

97 (26)

 No

277 (74)

Concurrent chemotherapy regimen

 CDDP-based

278 (74)

 CBDCA-based

64 (17)

 Cetuximab

32 (9)

Radiation technique

 Conventional 3D-CRT

253 (68)

 IMRT

121 (32)

Radiation dose, Gy

 70Gy

363 (97)

 60-70Gy

3 (1)

  < 60Gy

8 (2)

Irradiation field

 Local

67 (18)

 Whole neck

307 (82)

Percutaneous endoscopic gastrostomy prior to treatment

 Yes

229 (61)

 No

155 (39)

Treatment

 Inpatient

185 (49)

 Outpatient

189 (51)